Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of two oral schedules of gimatecan as second-line therapy for advanced NSCLC
2004-001043-30Phase 2Terminated
- Sponsor
- Leadiant Biosciences
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gimatecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Leadiant Biosciences. Started Mar 2005; status: terminated.
02
Drugs
gimatecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-001043-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001043-30.